DVC1-0101 to treat peripheral arterial disease: A phase I/IIa open-label dose-escalation clinical trial

Yoshikazu Yonemitsu, takuya matsumoto, Hiroyuki Itoh, Jin Okazaki, Makiko Uchiyama, Kumi Yoshida, Mitsuho Onimaru, Toshihiro Onohara, Hiroyuki Inoguchi, Ryoichi Kyuragi, Mototsugu Shimokawa, Hiroshi Ban, Michiko Tanaka, Makoto Inoue, Tsugumine Shu, Mamoru Hasegawa, Yoichi Nakanishi, Yoshihiko Maehara

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We here report the results of a Phase I/IIa open-label four dose-escalation clinical study assessing the safety, tolerability, and possible therapeutic efficacy of a single intramuscular administration of DVC1-0101, a new gene transfer vector based on a nontransmissible recombinant Sendai virus (rSeV) expressing the human fibroblast growth factor-2 (FGF-2) gene (rSeV/dF-hFGF2), in patients with peripheral arterial disease (PAD). Gene transfer was done in 12 limbs of 12 patients with rest pain, and three of them had ischemic ulcer(s). No cardiovascular or other serious adverse events (SAEs) caused by gene transfer were detected in the patients over a 6-month follow-up. No infectious viral particles, as assessed by hemagglutination activity, were detected in any patient during the study. No representative elevation of proinflammatory cytokines or plasma FGF-2 was seen. Significant and continuous improvements in Rutherford category, absolute claudication distance (ACD), and rest pain were observed (P < 0.05 to 0.01). To the best of our knowledge, this is the first clinical trial of the use of a gene transfer vector based on rSeV. The single intramuscular administration of DVC1-0101 to PAD patients was safe and well tolerated, and resulted in significant improvements of limb function. Larger pivotal studies are warranted as a next step.

Original languageEnglish
Pages (from-to)707-714
Number of pages8
JournalMolecular Therapy
Volume21
Issue number3
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Peripheral Arterial Disease
Sendai virus
Clinical Trials
Genes
Fibroblast Growth Factor 2
Extremities
Pain
Hemagglutination
Virion
Ulcer
Cytokines
Safety

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

DVC1-0101 to treat peripheral arterial disease : A phase I/IIa open-label dose-escalation clinical trial. / Yonemitsu, Yoshikazu; matsumoto, takuya; Itoh, Hiroyuki; Okazaki, Jin; Uchiyama, Makiko; Yoshida, Kumi; Onimaru, Mitsuho; Onohara, Toshihiro; Inoguchi, Hiroyuki; Kyuragi, Ryoichi; Shimokawa, Mototsugu; Ban, Hiroshi; Tanaka, Michiko; Inoue, Makoto; Shu, Tsugumine; Hasegawa, Mamoru; Nakanishi, Yoichi; Maehara, Yoshihiko.

In: Molecular Therapy, Vol. 21, No. 3, 01.01.2013, p. 707-714.

Research output: Contribution to journalArticle

Yonemitsu, Y, matsumoto, T, Itoh, H, Okazaki, J, Uchiyama, M, Yoshida, K, Onimaru, M, Onohara, T, Inoguchi, H, Kyuragi, R, Shimokawa, M, Ban, H, Tanaka, M, Inoue, M, Shu, T, Hasegawa, M, Nakanishi, Y & Maehara, Y 2013, 'DVC1-0101 to treat peripheral arterial disease: A phase I/IIa open-label dose-escalation clinical trial' Molecular Therapy, vol. 21, no. 3, pp. 707-714. https://doi.org/10.1038/mt.2012.279
Yonemitsu, Yoshikazu ; matsumoto, takuya ; Itoh, Hiroyuki ; Okazaki, Jin ; Uchiyama, Makiko ; Yoshida, Kumi ; Onimaru, Mitsuho ; Onohara, Toshihiro ; Inoguchi, Hiroyuki ; Kyuragi, Ryoichi ; Shimokawa, Mototsugu ; Ban, Hiroshi ; Tanaka, Michiko ; Inoue, Makoto ; Shu, Tsugumine ; Hasegawa, Mamoru ; Nakanishi, Yoichi ; Maehara, Yoshihiko. / DVC1-0101 to treat peripheral arterial disease : A phase I/IIa open-label dose-escalation clinical trial. In: Molecular Therapy. 2013 ; Vol. 21, No. 3. pp. 707-714.
@article{fa6e17dd6ca143ce88823052cc75babd,
title = "DVC1-0101 to treat peripheral arterial disease: A phase I/IIa open-label dose-escalation clinical trial",
abstract = "We here report the results of a Phase I/IIa open-label four dose-escalation clinical study assessing the safety, tolerability, and possible therapeutic efficacy of a single intramuscular administration of DVC1-0101, a new gene transfer vector based on a nontransmissible recombinant Sendai virus (rSeV) expressing the human fibroblast growth factor-2 (FGF-2) gene (rSeV/dF-hFGF2), in patients with peripheral arterial disease (PAD). Gene transfer was done in 12 limbs of 12 patients with rest pain, and three of them had ischemic ulcer(s). No cardiovascular or other serious adverse events (SAEs) caused by gene transfer were detected in the patients over a 6-month follow-up. No infectious viral particles, as assessed by hemagglutination activity, were detected in any patient during the study. No representative elevation of proinflammatory cytokines or plasma FGF-2 was seen. Significant and continuous improvements in Rutherford category, absolute claudication distance (ACD), and rest pain were observed (P < 0.05 to 0.01). To the best of our knowledge, this is the first clinical trial of the use of a gene transfer vector based on rSeV. The single intramuscular administration of DVC1-0101 to PAD patients was safe and well tolerated, and resulted in significant improvements of limb function. Larger pivotal studies are warranted as a next step.",
author = "Yoshikazu Yonemitsu and takuya matsumoto and Hiroyuki Itoh and Jin Okazaki and Makiko Uchiyama and Kumi Yoshida and Mitsuho Onimaru and Toshihiro Onohara and Hiroyuki Inoguchi and Ryoichi Kyuragi and Mototsugu Shimokawa and Hiroshi Ban and Michiko Tanaka and Makoto Inoue and Tsugumine Shu and Mamoru Hasegawa and Yoichi Nakanishi and Yoshihiko Maehara",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/mt.2012.279",
language = "English",
volume = "21",
pages = "707--714",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - DVC1-0101 to treat peripheral arterial disease

T2 - A phase I/IIa open-label dose-escalation clinical trial

AU - Yonemitsu, Yoshikazu

AU - matsumoto, takuya

AU - Itoh, Hiroyuki

AU - Okazaki, Jin

AU - Uchiyama, Makiko

AU - Yoshida, Kumi

AU - Onimaru, Mitsuho

AU - Onohara, Toshihiro

AU - Inoguchi, Hiroyuki

AU - Kyuragi, Ryoichi

AU - Shimokawa, Mototsugu

AU - Ban, Hiroshi

AU - Tanaka, Michiko

AU - Inoue, Makoto

AU - Shu, Tsugumine

AU - Hasegawa, Mamoru

AU - Nakanishi, Yoichi

AU - Maehara, Yoshihiko

PY - 2013/1/1

Y1 - 2013/1/1

N2 - We here report the results of a Phase I/IIa open-label four dose-escalation clinical study assessing the safety, tolerability, and possible therapeutic efficacy of a single intramuscular administration of DVC1-0101, a new gene transfer vector based on a nontransmissible recombinant Sendai virus (rSeV) expressing the human fibroblast growth factor-2 (FGF-2) gene (rSeV/dF-hFGF2), in patients with peripheral arterial disease (PAD). Gene transfer was done in 12 limbs of 12 patients with rest pain, and three of them had ischemic ulcer(s). No cardiovascular or other serious adverse events (SAEs) caused by gene transfer were detected in the patients over a 6-month follow-up. No infectious viral particles, as assessed by hemagglutination activity, were detected in any patient during the study. No representative elevation of proinflammatory cytokines or plasma FGF-2 was seen. Significant and continuous improvements in Rutherford category, absolute claudication distance (ACD), and rest pain were observed (P < 0.05 to 0.01). To the best of our knowledge, this is the first clinical trial of the use of a gene transfer vector based on rSeV. The single intramuscular administration of DVC1-0101 to PAD patients was safe and well tolerated, and resulted in significant improvements of limb function. Larger pivotal studies are warranted as a next step.

AB - We here report the results of a Phase I/IIa open-label four dose-escalation clinical study assessing the safety, tolerability, and possible therapeutic efficacy of a single intramuscular administration of DVC1-0101, a new gene transfer vector based on a nontransmissible recombinant Sendai virus (rSeV) expressing the human fibroblast growth factor-2 (FGF-2) gene (rSeV/dF-hFGF2), in patients with peripheral arterial disease (PAD). Gene transfer was done in 12 limbs of 12 patients with rest pain, and three of them had ischemic ulcer(s). No cardiovascular or other serious adverse events (SAEs) caused by gene transfer were detected in the patients over a 6-month follow-up. No infectious viral particles, as assessed by hemagglutination activity, were detected in any patient during the study. No representative elevation of proinflammatory cytokines or plasma FGF-2 was seen. Significant and continuous improvements in Rutherford category, absolute claudication distance (ACD), and rest pain were observed (P < 0.05 to 0.01). To the best of our knowledge, this is the first clinical trial of the use of a gene transfer vector based on rSeV. The single intramuscular administration of DVC1-0101 to PAD patients was safe and well tolerated, and resulted in significant improvements of limb function. Larger pivotal studies are warranted as a next step.

UR - http://www.scopus.com/inward/record.url?scp=84875230671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875230671&partnerID=8YFLogxK

U2 - 10.1038/mt.2012.279

DO - 10.1038/mt.2012.279

M3 - Article

VL - 21

SP - 707

EP - 714

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -